About Morphoceuticals
Morphoceuticals is a private company based in Medford, Massachusetts, incorporated in 2020 in Delaware. It has reported $13,320,000 raised in two offerings on Form D since January 2023. Its chief executive is James Jenson.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Oct 7, 2024 | $3,500,000of $5.5M target | 1 | $3.5M | EquityRule 506(b) | Form D ↗ |
| Jan 13, 2023 | Jan 23, 2023 | $9,820,000fully sold | 3 | $3.2M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $13,320,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Morphoceuticals's Form D filed Oct 7, 2024.
MH
Michael Hufford
Director
AP
Alexander Pickett
Director
JB
Justin Briggs
Director
TT
Tamim Al-Thani
Director
RH
Rosemarie Hunziker
Director
JJ
James Jenson
Chief Executive Officer and director
Earlier filings also listed Michael Levin (promoter, last listed Jan 2023), David Kaplan (promoter, last listed Jan 2023), David Gill (executive officer, last listed Jan 2023) and Amy Kruse (director, last listed Jan 2023).